Ac-225-PSMA-617
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
Ac-225-Lintuzumab (Ac-225 Actimab-A™)
225Ac-Lintuzumab (225Ac-Actimab-A™, 225Ac-DOTA-huM195, 225Ac-DOTA-Lintuzumab) is the new name of the [...]
Ac-225-FPI-1434
225Ac-FPI-1434 (225Ac-FPX-01) is an alpha labeled antibody under development for [...]
Ac-225-DOTAZOL
225Ac-DOTAZOL is a DOTA Zoledronic acid derivative suitable for alphatherapy [...]
Ac-225-DOTATOC
225Ac-DOTATOC is one alpha-labeled analogue of 90Y- and 177Lu-DOTATOC [...]
Ac-225-DOTATATE
225Ac-DOTATATE is the alpha-labeled analogue of 90Y- and 177Lu-DOTATATE. Several [...]
Ac-225-CONV-01-α
225Ac-CONV-01-α is an alpha-radiolabeled monoclonal antibody targeting PSMA developed [...]